Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 12c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.11, $0.12 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $58 million.

Cash, cash equivalents and marketable securities (Cash) was $435.2 million as of March 31, 2022, representing an increase to Cash of $57.0 million compared to March 31, 2021 and an increase to Cash of $2.4 million compared to December 31, 2021.

GUIDANCE:

Vanda Pharmaceuticals sees FY2022 EPS of $240.00-$280.00.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• John Wiley & Sons, Inc. (WLY) Tops Q4 EPS by 12c; offers outlook
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral